IFF Pharma Solutions Set to Highlight Its Portfolio at Excipient World 2025
IFF Pharma Solutions Set to Highlight Its Portfolio at Excipient World 2025 IFF Pharma Solutions, a division of International Flavors & Fragrances Inc. and a global leader in polymer innovation,…
Prilenia and Ferrer Partner on Pridopidine Commercialization and Development in Europe
Prilenia and Ferrer Partner on Pridopidine Commercialization and Development in Europe Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for neurodegenerative diseases, announced a significant new…
nChroma Bio to Present at ASGCT 2025 Annual Meeting
nChroma Bio to Present at ASGCT 2025 Annual Meeting nChroma Bio, an emerging leader in the field of genetic medicines, today announced the acceptance of three significant scientific abstracts at…
Revolution Medicines Shares Early Zoldonrasib Data in KRAS G12D NSCLC at 2025 AACR
Revolution Medicines Shares Early Zoldonrasib Data in KRAS G12D NSCLC at 2025 AACR Revolution Medicines, Inc. a late-stage clinical oncology company committed to developing targeted therapies for patients with RAS-addicted…
Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC
Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody,…
KEYTRUDA Plus Standard Therapy Boosts Event-Free Survival in Resectable Head and Neck Cancer
KEYTRUDA Plus Standard Therapy Boosts Event-Free Survival in Resectable Head and Neck Cancer Merck , known as MSD outside the United States and Canada, has announced landmark findings from its…
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial…
Gameto Launches First U.S. Clinical Site for Patient Enrollment in Fertilo Study
Gameto Launches First U.S. Clinical Site for Patient Enrollment in Fertilo Study Gameto, a clinical-stage biotechnology company at the forefront of developing cutting-edge iPSC (induced pluripotent stem cell)-based therapies to…
Coya Therapeutics Reports Positive Interim Results of IL-2 and CTLA4-Ig Combination in Mild to Moderate Frontotemporal Dementia
Coya Therapeutics Reports Positive Interim Results of IL-2 and CTLA4-Ig Combination in Mild to Moderate Frontotemporal Dementia Coya Therapeutics, Inc. , a clinical-stage biotechnology company specializing in the development of…
FDA Approves Second Manufacturing Facility for ADSTILADRIN (nadofaragene firadenovec-vncg)
FDA Approves Second Manufacturing Facility for ADSTILADRIN (nadofaragene firadenovec-vncg) In a significant development for the biopharmaceutical industry, Ferring Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA)…
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders,…
Lumicera and Costco Partner to Offer Cost-Plus Specialty Pharmacy with Enhanced Pricing and Patient Support
Lumicera and Costco Partner to Offer Cost-Plus Specialty Pharmacy with Enhanced Pricing and Patient Support In a move poised to shake up the specialty pharmacy market, Lumicera Health Services, a…